TREATMENT OF METASTATIC MELANOMA WITH RECOMBINANT INTERLEUKIN-2
OBJECTIVES: I. Evaluate the response and survival rates of patients with metastatic melanoma
following induction with high-dose and maintenance with low-dose interleukin-2. II. Assess
the toxicity of this regimen.
OUTLINE: All patients receive high-dose interleukin-2 over 24 hours, followed by low-dose
interleukin-2 for 4 days in the absence of toxicity. Patients receive a second cycle
beginning 9-13 days after completion of the first cycle, with response assessed
approximately 2 months after initiating therapy. Patients with stable or responding disease
receive a second course as above; those with a continued response may receive additional
courses provided toxicity is limited. Patients are followed for survival.
PROJECTED ACCRUAL: 20 patients will be entered.
Primary Purpose: Treatment
Richard L. White, MD
Blumenthal Cancer Center at Carolinas Medical Center
United States: Federal Government
|Carolinas Medical Center||Charlotte, North Carolina 28232-2861|